In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Cost-Sharing Solution: The New NICE Ticket

Executive Summary

J&J's Velcade and Celgene's Revlimid illustrate how pharma has adapted to the NICE UK cost-effectiveness watchdog. Now that the UK precedents exist, there will be more to come. But are they really pharma's ticket to increased access, and do they assure the value to the health care system that they claim? This article originally appeared in February 2009's RPM Report.
Advertisement

Related Content

Rising Payor Influence Means Successful Drug Launches are Rarer
Rising Payor Influence Means Successful Drug Launches are Rarer
U.K. NICE Snubs Novo's Victoza, But Drug Launches Fast In The U.S.
NICE Enough? Watchdog's Basic Approach Is Sound, But More Transparency Is Urged
Pricing Experiments: Pharmas Get Creative in Germany
Pricing Experiments: Pharmas Get Creative in Germany
No Cure, No Pay: The Future of Drug Marketing?
No Cure, No Pay: The Future of Drug Marketing?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV003280

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel